Krandel Judy 4

What Happened
Judy Krandel, Chief Financial Officer of Nephros Inc. (NEPH), was granted a 4,000-share derivative award on March 16, 2026. The Form 4 records the acquisition as a derivative grant (transaction code A) with an acquisition price of $0.00. This was an award/grant of derivative securities (options or similar), not a purchase of common shares for cash or a sale.

Key Details

• Transaction date: 2026-03-16; reported acquisition price: $0.00 per share.
• Filing date: 2026-03-18 (covers the 3/16/2026 transaction) — appears to have been filed promptly.
• Shares reported in this transaction: 4,000 derivative shares (grant).
• Shares owned after transaction: not disclosed in the provided filing excerpt.
• Notable footnotes (vesting schedules):
  • F3 (applies to this 4,000-share grant): 1,000 shares vest on 3/16/2027; the remaining 3,000 vest quarterly in 12 equal amounts beginning 6/16/2027.
  • F1 and F2 (other option grants referenced in the filing) describe additional option vesting schedules: F1 — 30,631 vest 11/1/2024 and 91,893 vest quarterly starting 2/1/2025; F2 — 13,589 vest 3/27/2026 and 40,770 vest quarterly starting 6/27/2026.

Context
This was a derivative award (likely stock options or similar) tied to future vesting dates — the award does not represent immediately tradeable common shares until vesting/exercise conditions are met. Such grants are typically part of executive compensation and do not, by themselves, indicate buying or selling intent. No immediate sale or cashless exercise was reported in this filing.